Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Camp4 Therapeutics Corp. Schedule 13G reports that Balyasny Asset Management and related reporting persons may be deemed to beneficially own 2,632,437 shares of common stock, representing approximately 5.07% of the class based on 51,919,321 Shares outstanding as of March 4, 2026. The filing states these holdings arise from positions held by investment vehicles (ADMF and APHC) for which BAM acts as investment manager, and notes 1,624,523 warrants are issuable subject to a Beneficial Ownership Limitation that blocks exercise above 4.99%.
CAMP4 Therapeutics Corporation filed an 8-K to share a corporate update and investor materials highlighting new preclinical data for CMP-002 in SYNGAP1-related disorder. The company presented these findings and an updated slide deck on May 14, 2026.
In a SYNGAP1 haploinsufficient mouse model with chemically induced seizures, a single dose of CMP-002 produced statistically significant improvements in both seizure threshold and seizure severity. These results build on earlier motor and behavioral data, suggesting CMP-002 may address multiple neurological symptoms by restoring SYNGAP1 protein toward healthy levels.
The company describes SYNGAP1-related disorder as a rare central nervous system disease affecting over 10,000 people in the U.S., with high rates of intellectual disability and epilepsy and no approved disease-modifying therapies. CAMP4 expects to advance CMP-002, an antisense oligonucleotide designed to upregulate SYNGAP1, into a global Phase 1/2 clinical trial in the second half of 2026.
CAMP4 Therapeutics Corporation reports first-quarter 2026 results, showing higher collaboration revenue but a wider net loss as it advances its RNA-targeting pipeline. Revenue from research and collaboration grew to $1.3 million, mainly from its agreement with GSK. Research and development expenses were $10.2 million and general and administrative costs $4.2 million, keeping total operating expenses broadly flat versus last year.
The company recorded a non-cash $6.2 million loss from remeasuring its derivative tranche liability linked to a potential second private-placement closing, driving net loss to $18.3 million and basic and diluted net loss per share to $0.32. Operating cash outflow was $11.0 million.
CAMP4 ended the quarter with $99.2 million in cash and cash equivalents and $30.9 million in stockholders’ equity, and believes existing cash will fund operations into 2028. The company is preparing a global Phase 1/2 trial of lead candidate CMP-002 for SYNGAP1-related disorder and continues to leverage its RAP Platform and a $17.5 million GSK collaboration to support future programs.
CAMP4 Therapeutics reported first quarter 2026 results and highlighted progress in its SYNGAP1 program. The company recorded a net loss of $18.3 million for the quarter, reflecting a non-cash $6.2 million loss from a change in fair value of a derivative tranche liability tied to a prior private placement.
Research and collaboration revenue was $1.3 million, while research and development expenses were $10.2 million and general and administrative expenses were $4.2 million. CAMP4 ended March 31, 2026 with $99.2 million in cash and cash equivalents and expects this to fund planned activities into 2028.
Operationally, the company submitted its first clinical trial regulatory filing for lead candidate CMP-002 in Australia and plans additional global filings in 2026, anticipating a global Phase 1/2 trial in the second half of 2026. CMP-002 received Orphan Designation from the EMA, and CAMP4 initiated a collaboration with CURE SYNGAP1 to support the ProMMiS natural history study.
CAMP4 Therapeutics Corporation is holding its 2026 annual stockholder meeting as a virtual-only webcast on June 10, 2026, at 11:00 a.m. Eastern. Stockholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor, and approving an amendment to the 2024 Equity Incentive Plan.
The record date is April 13, 2026, with 51,925,800 common shares entitled to one vote each. The proxy statement outlines board structure, committee responsibilities, executive and director pay, and severance and change-in-control protections for senior leaders.
Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.
Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share, expire on March 31, 2036, and vest in equal monthly installments over four years from the grant date.
Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.
The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.